SCHEMBL31371503

SCHEMBL31371503

Oc1ccccc1-c1nnc(Cl)c2ccsc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.34
DYRK1A Q13627 1/20 0.34
MAPT P10636 5/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
ALDH1A1 P00352 3/20 0.34
RAB9A P51151 2/20 0.34
HPGD P15428 2/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
THRB P10828 1/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
HTT P42858 1/20 0.33
TP53 P04637 1/20 0.33
GOT1 P17174 1/20 0.33
HTR2B P41595 2/20 0.32
CASP3 P42574 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31371610 0.84 IL1B (0.35) DYRK1AALDH1A1ESR1HSD17B10
SCHEMBL31371639 0.81 SCN9A (0.36) DYRK1ARAB9AESR1KMT2A
SCHEMBL28433440 0.78 ADORA1 (0.44) DYRK1AMAPTSMN1; SMN2ALDH1A1RAB9A
SCHEMBL31371634 0.76 ESR2 (0.42) L3MBTL1MAPTSMN1; SMN2ALDH1A1RAB9A
SCHEMBL31371516 0.72 PDE5A (0.39) HTT
SCHEMBL2201586 0.72 DYRK1A (0.47) DYRK1AMAPTSMN1; SMN2ALDH1A1HPGD
SCHEMBL30413717 0.72 DYRK1A (0.47) DYRK1AMAPTSMN1; SMN2ALDH1A1HPGD
SCHEMBL580923 0.68 ADORA1 (0.41) MAPTSMN1; SMN2ALDH1A1HPGDKMT2A
SCHEMBL31371717 0.68 SCN9A (0.42) MAPTALDH1A1KDM4E
SCHEMBL31371910 0.66 SCN9A (0.41) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025034849-A1 FUSED PYRIDAZINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2025-02-13 WO disclosed